High-specificity affinity reagents for the detection of glycan sialylation

用于检测聚糖唾液酸化的高特异性亲和试剂

基本信息

  • 批准号:
    8994739
  • 负责人:
  • 金额:
    $ 34.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-01-15 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Glycans have several distinct properties that make their development as disease biomarkers appealing. Firstly, their location on cell surfaces makes them the first point of contact for cellular interactions, and thus they are crucial in the control of normal metabolic processes, and conversely, they function as pathogen adhesion receptors. Secondly, specific glycan structures that are not present, or are in low amounts in normal state, proliferate or alter their sequence in disease states. And, lastly, changes in glycosylation may be found in many proteins, including those that are highly abundant. Thus changes in the normal levels of glycan structures, such as terminal sialic acid, may be markers of disease states. New highly-specific reagents are required in order to overcome current limitations in the discovery and exploitation of disease-related glycans. Using structurally-guided genetic manipulations, we will convert the NanB sialidase from S. pneumococcus into a high-specificity affinity reagent for the detection of sialic acid modifications of glycopeptides and glycoproteins. Because such a protein has lectin-like properties, but is derived from an enzyme, it is called a "Lectenz(r)". A NanB Lectenz(r) addresses a key need in disease glycomarker detection: namely, a robust and easy to produce reagent specific for �3-linked sialic acid. This reagent could be employed in an affinity matrix for sample enrichment, which in conjunction with existing MS based methods could provide linkage information. It could also be employed in histological studies, or Western blots, etc. Lectenz(r) offer numerous advantages over plant lectins: they are engineered to be high affinity and yet retain the exquisite substrate specificityof the endogenous enzyme, they may be efficiently produced, and for human homologues have the potential to be employed in vivo with low toxicity. Whereas some aspects of Lectenz(r) development parallel those of antibody evolution, Lectenz(r) have the tremendous benefit of employing a protein naive template that has the desired specificity.
描述(由申请方提供):聚糖具有几种独特的性质,使其作为疾病生物标志物的开发具有吸引力。首先,它们在细胞表面的位置使它们成为细胞相互作用的第一个接触点,因此它们在控制正常代谢过程中至关重要,相反,它们作为病原体粘附受体发挥作用。其次,在正常状态下不存在或含量低的特定聚糖结构在疾病状态下增殖或改变其序列。最后,糖基化的变化可以在许多蛋白质中发现,包括那些高度丰富的蛋白质。因此,聚糖结构(如末端唾液酸)的正常水平的变化可能是疾病状态的标志。需要新的高度特异性的试剂,以克服目前在发现和开发疾病相关聚糖方面的限制。使用结构导向 通过基因操作,我们将从S.肺炎球菌转化为用于检测糖肽和糖蛋白的唾液酸修饰的高特异性亲和试剂。由于这种蛋白质具有凝集素样性质,但来源于酶,因此被称为“Lectenz(r)"。NanB Lectenz(r)解决了疾病糖标记物检测的关键需求:即,一种稳定且易于生产的β 3-连接唾液酸特异性试剂。该试剂可用于样品富集的亲和基质中,其与现有的基于MS的方法结合可提供连接信息。它也可以用于组织学研究或蛋白质印迹等。Lectenz(r)提供了许多优于植物凝集素的优点:它们被设计成高亲和力,但保留了内源酶的精致底物特异性,它们可以有效地产生,并且对于人类同源物具有低毒性的体内应用潜力。尽管Lectenz(r)开发的某些方面与抗体进化的那些方面平行,但Lectenz(r)具有使用具有所需特异性的蛋白质幼稚模板的巨大好处。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Loretta Yang其他文献

Loretta Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Loretta Yang', 18)}}的其他基金

A new approach to monitoring glycosylation during glycoprotein production
监测糖蛋白生产过程中糖基化的新方法
  • 批准号:
    10830193
  • 财政年份:
    2023
  • 资助金额:
    $ 34.93万
  • 项目类别:
Development of a suite of high-specificity fucose binding reagents
一套高特异性岩藻糖结合试剂的开发
  • 批准号:
    10084298
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
Development of a suite of high-specificity fucose binding reagents
一套高特异性岩藻糖结合试剂的开发
  • 批准号:
    9909159
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
A rapid method for monitoring in vitro glycoengineering
一种快速监测体外糖工程的方法
  • 批准号:
    9346470
  • 财政年份:
    2017
  • 资助金额:
    $ 34.93万
  • 项目类别:
High-specificity affinity reagents for the detection of glycan sialylation
用于检测聚糖唾液酸化的高特异性亲和试剂
  • 批准号:
    8832864
  • 财政年份:
    2015
  • 资助金额:
    $ 34.93万
  • 项目类别:
In-process glycoprofiling during recombinant therapeutic glycoprotein production
重组治疗性糖蛋白生产过程中的糖谱分析
  • 批准号:
    8253195
  • 财政年份:
    2012
  • 资助金额:
    $ 34.93万
  • 项目类别:

相似海外基金

Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 34.93万
  • 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
  • 批准号:
    2750554
  • 财政年份:
    2021
  • 资助金额:
    $ 34.93万
  • 项目类别:
    Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
  • 批准号:
    61319
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
    Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10013588
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
  • 批准号:
    20K07009
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
  • 批准号:
    10603473
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
  • 批准号:
    2342674
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
    Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
  • 批准号:
    10117194
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10115604
  • 财政年份:
    2020
  • 资助金额:
    $ 34.93万
  • 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
  • 批准号:
    10294224
  • 财政年份:
    2018
  • 资助金额:
    $ 34.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了